Recurrence of stroke at the end of · people with acute ischemic stroke
Flunarizine showed no clear difference in recurrence of stroke at the end of compared with placebo (low certainty).
1 finding from 1 review
Adverse events during treatment period · people with acute ischemic stroke
Flunarizine may leads to higher adverse events during treatment period compared with placebo (low certainty).
1 finding from 1 review
Hypotension · people with acute ischemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Systolic blood pressure · people with acute ischemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death or dependency at end of · people with acute ischemic stroke
Isradipine showed no clear difference in death or dependency at end of compared with placebo (low certainty).
1 finding from 1 review
Death at the end of treatment · people with acute ischemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death at the end of · people with acute ischemic stroke
Isradipine showed no clear difference in death at the end of compared with placebo (low certainty).
1 finding from 1 review
Recurrence of stroke at the end of · people with acute ischemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events during treatment period · people with acute ischemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hypotension · people with acute ischemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Systolic blood pressure · people with acute ischemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death or dependency at end of · people with acute ischemic stroke
Nimodipine showed no clear difference in death or dependency at end of compared with placebo (moderate certainty).
1 finding from 1 review
Death at the end of treatment · people with acute ischemic stroke
Nimodipine showed no clear difference in death at the end of treatment compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Tardive dyskinesia ‐ not improved to a clinically important extent · people with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether the intervention changes tardive dyskinesia ‐ not improved to a clinically important extent (very low certainty).
1 finding from 1 review
Intervention not reported
Tardive dyskinesia ‐ deterioration · people with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse effects ‐ any important adverse effects · people with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Intervention not reported
Adverse effects ‐ important extrapyramidal adverse effects · people with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Mental state ‐ deterioration · people with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Intervention not reported
Acceptability of treatment ‐ leaving the study early · people with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Social confidence, social inclusion, social networks or personalised quality of life measures ‐ no clinically significant change · people with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found